Swiss drugs giant launches 15 products in Kenya
Posted on : Wednesday, 21st October 2015
Kenya is the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.
“Novartis and Kenya have a relationship of more than 40 years, so I am delighted that Kenyan patients will be the first to benefit from Novartis Access.
“The successful implementation of the programme in Kenya will be essential to guide the expansion of Novartis Access to other countries in the future,” Joerg Reinhardt, the Chairman of the Board of Novartis said.
According to the company, the Novartis portfolio is being offered to the Kenyan government, non-governmental organizations and other public-sector healthcare providers for $1 per treatment, per month.
Kenya’s First Lady, Margaret Kenyatta said: “I am excited by the proactive steps being taken by our government and Novartis in the fight against cancer and other chronic diseases. Novartis Access complements the advocacy campaign I have been undertaking together with other African First Ladies to expand access to prevention and treatment for people with chronic diseases.”
The Novartis Access portfolio includes patented and generic Novartis medicines. The products have been selected based on the World Health Organization’s Essential Medicines List and are among the most commonly prescribed medicines.
In conjunction with the launch of the access portfolio and to support effective treatment of chronic diseases in Kenya, Novartis will partner with the Kenyan Ministry of Health, the Kenyan Red Cross, the Kenyan Conference of Catholic Bishops (KCCB), the Christian Health Association of Kenya (CHAK), Management Sciences for Health (MSH) and other key stakeholders. These collaborations are intended to support the healthcare system through measures such as reinforcing drug distribution channels and training healthcare workers to diagnose and treat chronic illnesses.
Novartis is also collaborating with Boston University in the United States to measure the impact on health in Kenya and steer ongoing development of Novartis Access.
Some 28 million people die from chronic diseases in low- and middle-income countries each year, representing 75% of such deaths globally. In Kenya, NCDs account for 27% of deaths, or almost 100,000 people per year.
By 2030, NCDs are expected to contribute to more than 60% of the total national mortality.4 In July 2015, the Kenyan government launched a new strategy for the prevention, control and management of NCDs.
“The most pressing health problems can only be solved if the public sector, civil society and the private sector work together,” Dr. Abbas Gullet, Secretary General of the Kenya Red Cross said. He said: “Novartis is making an important contribution to fighting NCDs, but in order for Novartis Access to make a long-term impact, we need to drive it locally.”
Following Kenya, Novartis Access will be launched in Ethiopia and Vietnam. Over the coming years, Novartis plans to roll out Novartis Access to 30 countries, depending on demand. Novartis expects this new approach to be commercially sustainable over the long term, enabling continuous support in those regions.
